in vivo News and Research

RSS

Scientists evaluate growth, differentiation and function of iPSC-derived NPCs in PD

Induced pluripotent stem cells (iPSC) are a promising avenue for cell replacement therapy in neurologic diseases. For example, mouse and human iPSCs have been used to generate dopaminergic (DA) neurons that improve symptoms in rat Parkinson's disease models. Reporting in the current issue of the Journal of Parkinson's Disease, a group of scientists from Japan evaluated the growth, differentiation, and function of human-derived iPSC-derived neural progenitor cells (NPCs) in a primate model, elucidating their therapeutic potential.

25 Jan 2012

Sofie to receive U.S. patent for novel PET probes

Sofie Biosciences, Inc., offering a comprehensive range of products from pre-clinical PET imaging systems to new PET molecular imaging probes to better understand human disease, has been told that a U.S. Patent (8,101,740) will be granted by the United States Patent Office on technology that has been exclusively licensed to Sofie. The patent covers a family of novel PET probes, known as [18F]FAC.

25 Jan 2012

Aphios receives NIH's Phase II SBIR grant to develop APH-0703 for AD

Aphios Corporation has received a Phase II SBIR grant from the National Institutes of Health (NIH) amounting to $2.4 million over two years. The National Institute on Aging (NIA), part of the NIH, awarded the grant to the Aphios Corporation to develop an "Alzheimer's Disease Therapeutic."

24 Jan 2012

Luteolin interferes with cell signaling in colon cancer cells

Luteolin is a flavonoid commonly found in fruit and vegetables. This compound has been shown in laboratory conditions to have anti-inflammatory, anti-oxidant and anti-cancer properties but results from epidemiological studies have been less certain. New research published in BioMed Central's open access journal BMC Gastroenterology shows that luteolin is able to inhibit the activity of cell signaling pathways (IGF and PI3K) important for the growth of cancer in colon cancer cells.

23 Jan 2012

NCI-funded project aims to shed new light on implications for bone metastasis in prostate cancer

Prostate cancer is the most frequent and second deadliest cancer men face. A team of Wayne State University researchers recently received $363,660 from the National Cancer Institute of the National Institutes of Health for the project - "Bone-induced c-kit in prostate cancer cells: implications for bone metastasis" - that aims to shed new light on implications for bone metastasis in prostate cancer.

21 Jan 2012

Scientists decode unknown mechanism of imiquimod in tumour defense

A research team from the Institute for Cancer Research at the MedUni Vienna has decoded a previously unknown mechanism of the active ingredient imiquimod in tumour defense. They have been able to prove that imiquimod transforms plasmacytoid dendritic cells (pDCs) into "tumour-killers" which can fight the tumour independently from other immune cells. This discovery could be an important step on the way to a more efficient treatment for cancer.

20 Jan 2012

RaNA Therapeutics completes $20.7 million round of financing

RaNA Therapeutics, Inc. today announced it has completed a $20.7 million round of financing co-led by Atlas Venture, SR One, and Monsanto, with participation of Partners Innovation Fund. The company is developing a technology platform to enable selective activation of target genes and expression of therapeutic factors by targeting a type of regulatory RNA called long non-coding RNA.

18 Jan 2012

Geisinger, InVivo to conduct injectable biocompatible hydrogel preclinical study for PNI

InVivo Therapeutics Holdings Corp., a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), and Geisinger Health System today announced a research collaboration to conduct a preclinical study using InVivo's injectable biocompatible hydrogel for the treatment of chronic pain caused by peripheral nerve compression.

17 Jan 2012

Animal study confirms dramatic effects of natural formula against prostate cancer

New animal study confirms the dramatic effects of a natural formula against aggressive prostate cancer tumors. Researchers at the Methodist Research Institute at Indiana University conducted the study on mice, using a human prostate cancer xenograft model.

17 Jan 2012

Researchers discover previously unknown effect of opioids

A team of researchers at the MedUni Vienna's Department of Neurophysiology has discovered a previously unknown effect of opioids: the study, which has now been published in the highly respected magazine "Science" and was led by Ruth Drdla-Schutting and Jürgen Sandkühler, shows that opioids not only temporarily relieve pain, but at the right dose can also erase memory traces of pain in the spinal cord and therefore eliminate a key cause of chronic pain.

13 Jan 2012

Nature journal publishes Ember's brown fat biology data

Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key data supporting its lead brown fat biology program in the journal Nature.

12 Jan 2012

Elevated ISG15 pathway may provide therapeutic targets for breast cancer

Interferon-stimulated gene 15 (ISG15), a ubiquitin like protein, is highly elevated in a variety of cancers including breast cancer. How the elevated ISG15 pathway contributes to tumorigenic phenotypes remains unclear and is the subject of a study published in the January 2012 issue of Experimental Biology and Medicine.

12 Jan 2012

MAL3-101 appears to have potent anti-tumor effects on multiple myeloma

A new study from SUNY Downstate Medical Center in Brooklyn, New York, shows that MAL3-101, a recently developed inhibitor of the heat shock protein 70 (Hsp70), appears to have potent anti-tumor effects on multiple myeloma, a bone marrow cancer.

10 Jan 2012

miRagen, Silence partner to assess delivery potential of novel miRNA-based therapeutics

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, announces that it has signed an agreement with miRagen Therapeutics, Inc., to assess the delivery potential of Silence's proprietary DBTC delivery system with miRagen's novel microRNA-based therapeutics.

9 Jan 2012

New U.S. patent covers key element of Xencor's Xtend half-life prolongation technology

Xencor, Inc., a company using its proprietary Protein Design Automation (PDA) platform technology to engineer next-generation antibodies, announced today that the U.S. Patent and Trademark Office has issued Xencor a broad patent covering optimized monoclonal antibody variants and their application for extending in vivo half-life of antibodies.

7 Jan 2012

Woman's ovarian cycle plays an important role in her susceptibility to infection

A new research report in the Journal of Leukocyte Biology suggests that a woman's ovarian cycle plays an important role in her susceptibility to infection.

4 Jan 2012

The Scientist selects Aspect Imaging's M2 imaging platform as one of Top 10 Innovations of 2011

The Scientist today unveiled the Top 10 Innovations of 2011 and selected Aspect Imaging's M2™ compact high-performance MRI imaging system as one the winners of this award. The Scientist invited members of the life science community to submit descriptions of exciting tools that made an impact in research this year and asked a panel of expert judges to evaluate the technologies.

2 Jan 2012

New initiative to detect cancers in earliest stages inside cells

A team of cancer imaging experts at Johns Hopkins has embarked on a five-year research initiative to speed development of early diagnostic tests and new treatments for breast, prostate and other common cancers.

29 Dec 2011

Researchers evaluate role of Mediterranean diet ingredients in prevention of cell damage

The researchers evaluated the role of Mediterranean diet ingredients in the prevention and mitigation of cell damage.

23 Dec 2011

Researchers develop CAD-type tools to engineer RNA control systems

The computer assisted design (CAD) tools that made it possible to fabricate integrated circuits with millions of transistors may soon be coming to the biological sciences. Researchers at the U.S. Department of Energy (DOE)'s Joint BioEnergy Institute (JBEI) have developed CAD-type models and simulations for RNA molecules that make it possible to engineer biological components or "RNA devices" for controlling genetic expression in microbes.